Monitoring and treating colorectal cancer based on tumor DNA
Part of Cancer, Digestive system clinical trials.
This study looks at using a blood test to find cancer DNA and guide treatment for people with stage IV colorectal cancer that has a specific genetic pattern. The goal is to see if this approach can help monitor the cancer and personalize treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have stage IV colorectal cancer that is 'mismatch repair deficient' or 'MSI-H'.
- You have not had immunotherapy for your current cancer.
- You are well enough to be up and about (ECOG 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with stage III colorectal cancer who haven't had treatment yet. It tests a blood test to find tiny bits of cancer DNA (MRD) after surgery, which may help doctors know if more treatment is needed.
This trial tests a new immunotherapy drug (AK104) given before and after surgery for a specific type of colon cancer that is MSI-H or dMMR. The goal is to see if the drug helps shrink the tumor and prevent the cancer from coming back.
This trial tests a personalized immune therapy (like a custom vaccine) for people with colorectal cancer that has a positive ctDNA MRD test after surgery. It aims to use the body's own immune system to target any remaining cancer cells and prevent the cancer from coming back.
This trial uses a blood test (MRD) to monitor for cancer return after surgery in patients with stage IV colorectal cancer that can be removed. The goal is to catch any recurrence early and guide further treatment.
This study looks at whether a blood test for tumor DNA (ctDNA) can predict how well immunotherapy works in people with advanced or locally advanced colorectal cancer that has specific genetic features (dMMR/MSI-H). If you qualify, the trial will monitor your ctDNA levels while you receive standard immunotherapy to see if changes in those levels can show early on if the treatment is working.
This trial uses a blood test to track changes in cancer-related DNA markers (methylation) to see how well treatment is working. It is for people with colorectal or small intestinal cancer that has not spread and who have not yet started treatment.
Hear when a new Colorectal Cancer (MSI-H) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.